MEDSCI (02415) Income Statement & Earnings

1.000
-0.010-0.99%

Trading May 18 11:02 CST

607.17MMarket Cap30.30P/E (TTM)

MEDSCI (02415) Income Statement

All

YOY

Hide blank lines

(FY)Dec 31, 2025

(Q6)Jun 30, 2025

(FY)Dec 31, 2024

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(FY)Dec 31, 2021

(FY)Dec 31, 2020

(FY)Dec 31, 2019

Turnover

3.74%270.37M

13.18%125.25M

-25.36%260.62M

-26.91%110.67M

0.07%349.19M

--151.4M

17.20%348.95M

37.93%297.73M

30.51%215.85M

--165.39M

Operating income

3.74%270.37M

13.18%125.25M

-25.36%260.62M

-26.91%110.67M

0.07%349.19M

151.4M

17.20%348.95M

37.93%297.73M

30.51%215.85M

165.39M

Cost of sales

-11.66%-109.93M

-11.79%-47.77M

25.75%-98.45M

32.25%-42.73M

7.04%-132.59M

---63.07M

-32.16%-142.63M

-9.21%-107.92M

-42.24%-98.82M

---69.48M

Operating expenses

-11.66%-109.93M

-11.79%-47.77M

25.75%-98.45M

32.25%-42.73M

7.04%-132.59M

-63.07M

-32.16%-142.63M

-9.21%-107.92M

-42.24%-98.82M

-69.48M

Gross profit

-1.07%160.45M

14.05%77.48M

-25.13%162.17M

-23.09%67.94M

4.99%216.61M

88.33M

8.70%206.32M

62.19%189.81M

22.02%117.03M

95.91M

Selling expenses

23.30%-60.45M

10.80%-33.76M

12.91%-78.81M

23.88%-37.85M

4.65%-90.49M

---49.73M

-14.04%-94.9M

-78.63%-83.22M

-22.60%-46.59M

---38M

Administrative expenses

30.99%-42.23M

36.86%-22.62M

-8.49%-61.19M

-12.74%-35.82M

23.15%-56.4M

---31.77M

-85.24%-73.39M

-77.52%-39.62M

-5.91%-22.32M

---21.07M

Research and development expenses

-31.94%-30.66M

-63.77%-19.69M

41.69%-23.24M

37.20%-12.02M

-13.83%-39.86M

---19.14M

-43.43%-35.01M

-35.04%-24.41M

9.24%-18.08M

---19.92M

Revaluation surplus

----

111.69%12.79M

--12.79M

42.64%-109.35M

---190.63M

----

-Changes in the fair value of other assets

----

111.69%12.79M

--12.79M

42.64%-109.35M

---190.63M

----

Impairment and provision

6.93%-13.2M

-1,328.32%-7.41M

-4.14%-14.18M

9.27%-519K

-437.33%-13.62M

---572K

61.04%-2.53M

-1,182.84%-6.5M

-71.86%-507K

---295K

-Other impairment is provision

6.93%-13.2M

-1,328.32%-7.41M

-4.14%-14.18M

9.27%-519K

-437.33%-13.62M

---572K

61.04%-2.53M

-1,182.84%-6.5M

-71.86%-507K

---295K

Special items of operating profit

-85.73%5.84M

13.77%20.62M

29.01%40.9M

37.92%18.12M

145.10%31.7M

--13.14M

66.14%12.93M

92.13%7.79M

58.96%4.05M

--2.55M

Operating profit

-23.03%19.74M

9,713.82%14.61M

-57.76%25.65M

-101.17%-152K

163.30%60.73M

13.04M

34.64%-95.94M

-536.94%-146.79M

75.17%33.59M

19.18M

Financing cost

-43.42%-218K

-4.55%-92K

44.93%-152K

42.48%-88K

22.69%-276K

---153K

-31.73%-357K

35.63%-271K

7.47%-421K

---455K

Earning before tax

-23.43%19.52M

6,150.42%14.52M

-57.82%25.5M

-101.86%-240K

162.78%60.45M

12.89M

34.52%-96.29M

-543.31%-147.06M

77.18%33.17M

18.72M

Tax

-199.43%-1.59M

-362.70%-1.28M

90.20%-530K

150.41%488K

-50.68%-5.41M

---968K

9.64%-3.59M

6.74%-3.97M

-149.65%-4.26M

---1.71M

After-tax profit from continuing operations

-28.16%17.94M

5,238.31%13.24M

-54.64%24.97M

-97.92%248K

155.11%55.04M

11.92M

33.87%-99.88M

-622.34%-151.03M

69.91%28.91M

17.02M

Earning after tax

-28.16%17.94M

5,238.31%13.24M

-54.64%24.97M

-97.92%248K

155.11%55.04M

11.92M

33.87%-99.88M

-622.34%-151.03M

69.91%28.91M

17.02M

Profit attributable to shareholders

-28.16%17.94M

5,238.31%13.24M

-54.64%24.97M

-97.92%248K

155.11%55.04M

11.92M

33.87%-99.88M

-622.34%-151.03M

69.91%28.91M

17.02M

Basic earnings per share

-40.00%0.03

4,800.00%0.0245

-54.55%0.05

-97.92%0.0005

152.38%0.11

0.024

98.81%-0.21

-682.18%-17.64

72.16%3.03

1.76

Diluted earnings per share

-40.00%0.03

4,800.00%0.0245

-37.50%0.05

129.41%0.0005

138.10%0.08

-0.0017

98.81%-0.21

-682.18%-17.64

72.16%3.03

1.76

Currency Unit

CNY

Accounting Standards

IAS

Audit Opinions

Unqualified Opinion

Auditor

Ernst & Young

	(FY)Dec 31, 2025	(Q6)Jun 30, 2025	(FY)Dec 31, 2024	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(FY)Dec 31, 2021	(FY)Dec 31, 2020	(FY)Dec 31, 2019
Turnover	3.74%270.37M	13.18%125.25M	-25.36%260.62M	-26.91%110.67M	0.07%349.19M	--151.4M	17.20%348.95M	37.93%297.73M	30.51%215.85M	--165.39M
Operating income	3.74%270.37M	13.18%125.25M	-25.36%260.62M	-26.91%110.67M	0.07%349.19M	151.4M	17.20%348.95M	37.93%297.73M	30.51%215.85M	165.39M
Cost of sales	-11.66%-109.93M	-11.79%-47.77M	25.75%-98.45M	32.25%-42.73M	7.04%-132.59M	---63.07M	-32.16%-142.63M	-9.21%-107.92M	-42.24%-98.82M	---69.48M
Operating expenses	-11.66%-109.93M	-11.79%-47.77M	25.75%-98.45M	32.25%-42.73M	7.04%-132.59M	-63.07M	-32.16%-142.63M	-9.21%-107.92M	-42.24%-98.82M	-69.48M
Gross profit	-1.07%160.45M	14.05%77.48M	-25.13%162.17M	-23.09%67.94M	4.99%216.61M	88.33M	8.70%206.32M	62.19%189.81M	22.02%117.03M	95.91M
Selling expenses	23.30%-60.45M	10.80%-33.76M	12.91%-78.81M	23.88%-37.85M	4.65%-90.49M	---49.73M	-14.04%-94.9M	-78.63%-83.22M	-22.60%-46.59M	---38M
Administrative expenses	30.99%-42.23M	36.86%-22.62M	-8.49%-61.19M	-12.74%-35.82M	23.15%-56.4M	---31.77M	-85.24%-73.39M	-77.52%-39.62M	-5.91%-22.32M	---21.07M
Research and development expenses	-31.94%-30.66M	-63.77%-19.69M	41.69%-23.24M	37.20%-12.02M	-13.83%-39.86M	---19.14M	-43.43%-35.01M	-35.04%-24.41M	9.24%-18.08M	---19.92M
Revaluation surplus	----	----	----	----	111.69%12.79M	--12.79M	42.64%-109.35M	---190.63M	----	----
-Changes in the fair value of other assets	----	----	----	----	111.69%12.79M	--12.79M	42.64%-109.35M	---190.63M	----	----
Impairment and provision	6.93%-13.2M	-1,328.32%-7.41M	-4.14%-14.18M	9.27%-519K	-437.33%-13.62M	---572K	61.04%-2.53M	-1,182.84%-6.5M	-71.86%-507K	---295K
-Other impairment is provision	6.93%-13.2M	-1,328.32%-7.41M	-4.14%-14.18M	9.27%-519K	-437.33%-13.62M	---572K	61.04%-2.53M	-1,182.84%-6.5M	-71.86%-507K	---295K
Special items of operating profit	-85.73%5.84M	13.77%20.62M	29.01%40.9M	37.92%18.12M	145.10%31.7M	--13.14M	66.14%12.93M	92.13%7.79M	58.96%4.05M	--2.55M
Operating profit	-23.03%19.74M	9,713.82%14.61M	-57.76%25.65M	-101.17%-152K	163.30%60.73M	13.04M	34.64%-95.94M	-536.94%-146.79M	75.17%33.59M	19.18M
Financing cost	-43.42%-218K	-4.55%-92K	44.93%-152K	42.48%-88K	22.69%-276K	---153K	-31.73%-357K	35.63%-271K	7.47%-421K	---455K
Earning before tax	-23.43%19.52M	6,150.42%14.52M	-57.82%25.5M	-101.86%-240K	162.78%60.45M	12.89M	34.52%-96.29M	-543.31%-147.06M	77.18%33.17M	18.72M
Tax	-199.43%-1.59M	-362.70%-1.28M	90.20%-530K	150.41%488K	-50.68%-5.41M	---968K	9.64%-3.59M	6.74%-3.97M	-149.65%-4.26M	---1.71M
After-tax profit from continuing operations	-28.16%17.94M	5,238.31%13.24M	-54.64%24.97M	-97.92%248K	155.11%55.04M	11.92M	33.87%-99.88M	-622.34%-151.03M	69.91%28.91M	17.02M
Earning after tax	-28.16%17.94M	5,238.31%13.24M	-54.64%24.97M	-97.92%248K	155.11%55.04M	11.92M	33.87%-99.88M	-622.34%-151.03M	69.91%28.91M	17.02M
Profit attributable to shareholders	-28.16%17.94M	5,238.31%13.24M	-54.64%24.97M	-97.92%248K	155.11%55.04M	11.92M	33.87%-99.88M	-622.34%-151.03M	69.91%28.91M	17.02M
Basic earnings per share	-40.00%0.03	4,800.00%0.0245	-54.55%0.05	-97.92%0.0005	152.38%0.11	0.024	98.81%-0.21	-682.18%-17.64	72.16%3.03	1.76
Diluted earnings per share	-40.00%0.03	4,800.00%0.0245	-37.50%0.05	129.41%0.0005	138.10%0.08	-0.0017	98.81%-0.21	-682.18%-17.64	72.16%3.03	1.76
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS
Audit Opinions	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	Unqualified Opinion	Unqualified Opinion	Unqualified Opinion
Auditor	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young	Ernst & Young	Ernst & Young	Ernst & Young

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"